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Background: Pulmonary tuberculosis (TB) is associated with an increased risk of lung cancer. Our study
investigated whether the coexistence of an old pulmonary TB lesion is an independent prognostic factor for lung
cancer survival in Chinese non-small cell lung cancer patients.
Methods: We performed a retrospective review of 782 non-small cell lung cancer patients who underwent surgical
resection as their primary treatment in 2006 and were followed for 5 years. The associations between lung cancer
survival and the presence of old pulmonary TB lesions were assessed using Cox’s proportional hazard regression
analysis adjusted for WHO performance status (PS), age, sex, smoking-status, tumor stage, and surgical approach.
Results: Sixty-four of the patients had old pulmonary TB lesions. The median survival of squamous cell carcinoma
patients with TB was significantly shorter than that of patients without TB (1.7 vs. 3.4 years, p < 0.01). The presence of an
old pulmonary TB lesion is an independent predictor of poor survival with a hazard ratio (HR) of 1.72 (95% CI, 1.12–2.64)
in the subgroup of squamous cell carcinoma patients studied.
Conclusion: The presence of an old pulmonary TB lesion may be an important prognostic factor for predicting the
survival of squamous cell carcinoma patients.Background
Non-small cell lung cancer (NSCLC) remains the leading
cause of cancer death worldwide [1]. Highly effective treat-
ments have been available for decades, but tuberculosis
(TB) remains a major global health problem. In 2010,
there were 8.8 million (range, 8.5-9.2 million) cases of TB
and 1.1 million (range, 0.9–1.2 million) deaths from TB
among the HIV-negative population [2]. Both TB and lung
cancer have a large public health impact. The potential re-
lationship between pulmonary TB and lung cancer has
been a topic of active interest for several decades. At
present, it is clear that pulmonary TB increases the risk of
lung cancer [3-6], but not all studies agree on its utility as
a prognostic factor. Recently, a study indicated that a* Correspondence: shhuzy@163.com; gnwp@yahoo.com.cn
2Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital,
Tongji University, 507 Zhengmin Rd, 200433, Shanghai, China
1Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji
University School of Medicine, 507 Zhengmin Rd, 200433, Shanghai, China
Full list of author information is available at the end of the article
© 2013 Zhou et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orhistory of pulmonary TB may be a negative prognostic fac-
tor for lung cancer survival in Caucasian patients [7], but
Kuo and coworkers [8] suggested that concomitant active
prolongs survival in NSCLC. Because TB is associated
with lung cancer, a different question should be asked:
does TB affect some types of lung cancer but not others?
Luo [9] suggested that patients with pulmonary adenocar-
cinoma who had scar cancer or had old TB lesions had a
higher probability of having EGFR mutations, especially
exon 19 deletions. Moreover, squamous cell carcinoma
(SCC) of the lung was found in mice subjected to chronic
infection with mycobacterial tuberculosis [10]. However,
an epidemiological study in a large group of TB patients
and subjects without TB demonstrated that TB patients
had an increased relative risk of developing adenocarcin-
oma but not SCC [11]. Therefore, the association between
these two diseases warrants further investigation.
Methods
We performed a retrospective review of NSCLC patients
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followed their clinical outcomes for 5 years after surgery.
This review was approved by the institutional review board
of our hospital. Seven hundred eighty-two NSCLC patients
who underwent surgical resection as the primary treatment
were enrolled. All 782 patients received complete evalua-
tions before surgery, including physical examination, bio-
chemistry testing, chest computed tomography (CT) scans,
radionuclide bone scans, abdominal ultrasonography, brain
MRI, and bronchoscopy. The presence of old pulmonary
TB lesions was revealed on the chest CT scans. The chest
CT scans were evaluated for fibronodular lesions, calcified
nodules, fibrotic changes, pleural thickening, and scars. All
CT scans were analyzed by three independent reviewers.
Lesions with calcified granulomas, fibronodular lesions, or
pleural thickening suggesting previous granulomatous in-
flammation were regarded as old TB lesions [12]. After








Number of subjects 782(100) 718(91.8) 64(8.2
Age at diagnosis (years) (mean±SD) 60±10.2 60±10.2 61±9.8
PS
0 98 90 8
1 624 628 56
Sex
Male 600(76.7) 545(75.9) 55(85.
Female 182(23.3) 173(24.1) 9(14.1
Smoking status
Never 240(30.7) 225(31.3) 15(23.
Smoker or ex-smoker 542(69.3) 493(68.7) 49(76.
Stage of lung cancer at diagnosisc
I 315(40.3) 287(40.0) 28(43.
II 157(20.1) 141(19.6) 16(25.
III 246(31.5) 227(30.6) 19(29.
IV 64(8.2) 63(8.8) 1(1.6)
Histologic type
SCC 302(38.6) 269(37.5) 33(51.
Adenocarcinoma 406(51.9) 378(52.6) 28(43.
Othera 74(9.5) 71(9.9) 3(4.7)
Surgical approach
Lobectomy 685(87.6) 633(88.2) 52(81.
Pneumonectomy 97(12.4) 85(11.8) 12(18.
Median survival (year) 3.4 3.4 3.0
a Including adenosquamous carcinoma, sarcomatoid carcinoma, and undifferentiate
b A p-value less than 0.05 was considered statistically significant.
C All patients were re-staged according to the 7th edition lung cancer staging. SCCa final diagnosis by consensus. The TB lesions were either
in the same lobe or in different lobes as the primary lung
cancer lesions. The main surgical approaches used in our
hospital are lobectomy, pneumonectomy, and lymph node
dissection. Adjuvant therapies such as chemotherapy or
radiotherapy were scheduled in our hospital during the
period of this study. Complete follow-up information was
obtained in 727 cases (93%); 55 cases (7%) were unable to
be followed.
The χ2 test was used for categorical variables. The sur-
vival time was defined as the interval between the date of
operation and the date of death or the 5-year endpoint,
whichever came first. The survival curve was calculated by
the Kaplan-Meier method. Univariate and multivariate
analyses were performed by the Cox proportional hazards
model using SPSS software (version 16.0; SPSS, Chicago,
IL, USA). Clinical pathological factors, such as age, sex,










) 302(100) 269(89.1) 33(10.9)





9) 285(94.4) 252(93.7) 33(100)
) 17(5.6) 17(6.3) 0(0)
0.18 0.70
4) 48(15.9) 42(15.6) 6(18.2)
6) 254(84.1) 227(84.4) 27(81.8)
0.18 0.16
8) 123(40.7) 114(42.4) 9(27.3)
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2) 245(81.1) 222(82.5) 23(69.7)
8) 57(18.9) 47(17.5) 10(30.3)
0.50 3.2 3.4 1.7 <0.01b
d carcinoma.
= squamous cell carcinoma.
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lesions were included in the analyses. A result was consid-
ered to be statistically significant if the p-value was less
than 0.05.
Results
One-year, 3-year, and 5-year survival rates after initial
surgical resection were 75%, 53%, and 33%, respectively.
Recurrent NSCLC developed in 422 patients (54%). At the
time of follow-up, 523 patients had died because of local
recurrence or distant metastasis (n = 396, 75.7%) or due
to other causes (n =127, 24.3%). Active TB did not develop
in any of the patients.
Table 1 depicts the clinical pathological characteristics of
the 782 patients. Of these patients, 64 had an old pulmon-
ary tuberculosis lesion. Only 2 patients had a clinical his-
tory of pulmonary TB and had received anti-TB treatment
previously. Acid-fast smears from sputum, bronchial
wash, or broncho-alveolar lavage fluid were negative in all
NSCLC patients. The mean age at diagnosis of lung cancer
was 60 years. Approximately two-thirds of the 782 subjects
in this study were smokers or had a history of smoking at
the time of diagnosis of lung cancer. In the TB group,
squamous cell carcinoma was the most common histo-
logical type (51.6%), followed by adenocarcinoma (43.8%).
In the non-TB group, adenocarcinoma was the most com-
mon histological type (52.6%), followed by squamous cell
carcinoma (37.5%).
Table 2 shows the adjuvant treatment after surgery.
Notably, some patients declined the adjuvant therapy due
to personal reasons, which were distributed randomly.
The comparison of lung cancer survival outcomes in
patients with and without TB is shown in Figure 1A
(all NSCLC patients) and Figure 1B (SCC patients). Among
the entire NSCLC group, there was no significant differ-
ence in survival between patients with and without TB.Table 2 Adjuvant therapyb after surgery for squamous
cell carcinoma
Stage of lung cancer
at diagnosisa
Without TB(%) With TB(%) p-value
I 114 9 0.91
Without adjuvant therapy 40(35.1) 3(33.3)
With adjuvant therapy 74(64.9) 6(66.7)
II 50 10 0.78
Without adjuvant therapy 12(24.0) 2(20)
With adjuvant therapy 38(76.0) 8(80)
III &IV 105 14 0.96
Without adjuvant therapy 23(21.9) 3(21.4)
With adjuvant therapy 82(78.1) 11(78.6)
aAll patients were re-staged according to the 7th edition of the TNM-staging
of lung cancer.
bAdjuvant therapy included chemotherapy and radiotherapy. We arranged
these treatments according to the NCCN guidelines.However, the SCC patients with TB lesions had a signifi-
cantly shorter median survival time than the SCC patients
without TB lesions (1.7 vs. 3.4 years, p < 0.05). In patients
with adenocarcinoma and other histologic subtypes, sur-
vival did not significantly differ between patients with and
without tuberculosis.
Table 3 shows the crude and adjusted hazard ratios
(HRs) for survival time in SCC patients. The types of sur-
gical approach, sex, stage of cancer, smoking status, PS,
and the presence or absence of TB lesions were associated
with survival in univariate and multivariate analysis. The
crude HR for the presence of old TB lesions showed a
1.73-fold increased risk (95% CI: 1.14–2.63), and the
adjusted HR of the presence of old TB lesions showed a
1.72-fold increased risk (95% CI: 1.12–2.64).
Discussion
To our knowledge, this is the first study to demonstrate
the presence of an old pulmonary TB lesion as an inde-
pendent prognostic risk factor for squamous cell lung
cancer survival. In 1996, it was reported that Taiwanese
lung cancer patients who present initially with active TB
do not survive as long as those without active TB [13].
The patients included in the 1996 study were defined as
TB-positive only if they were diagnosed with TB up to 2
years before or after their diagnosis of lung cancer, and
the survival analysis was confounded by an important
prognostic factor of lung cancer, i.e., TNM stage. These
constraints may have introduced selection bias as well as
information bias. Recently, Heuvers et al. reported that a
history of pulmonary TB may be an important prognos-
tic factor for the survival of lung cancer [7]. However,
their study was limited by recall bias, as not all subjects
may have remembered their respiratory TB or may have
been unaware of TB infection in the past. Moreover, this
study did not include the WHO PS of the lung cancer
cases, and the authors were not aware of the treatment
of the patients. Kuo [8] demonstrated that concomitant
active TB in NSCLC was associated with improved sur-
vival. However, all 276 patients included in Kuo’s study
were in advanced stages of NSCLC (stage III and stage
IV). Their samples are therefore not representative of
the general lung cancer population. There are two major
prognostic factors for lung cancer: WHO PS and disease
stage. In our study, the patients who underwent surgical
resection were typically at a PS level of 0–1. In contrast
to these previous studies, the larger number and more
representative nature of the samples collected in the
present study provide more reliable statistical power for
assessing the relationship between lung cancer and TB.
Although TB did not affect overall survival in the
whole NSCLC population in our study, Luo [9] recently
suggested that patients with pulmonary adenocarcinoma
and TB lesions had a higher probability of having EGFR
Figure 1 Kaplan-Meier survival curve. (A) All NSCLC patients with and without active TB (log rank test, P = 0.50). Green line: patients with TB.
Blue line: patients without TB. (B) SCC patients with and without active TB (log rank test, P < 0.01). Green line: patients with TB. Blue line: patients
without TB.
Table 3 Prognostic factors for SCC survival outcome as determined by univariate and multivariate analyses
Variables Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value
TB
Without TB 1.00 <0.01a 1.00 <0.05a
With TB 1.73(1.14~2.63) 1.72 (1.12~2.64)
Sex
Female 1.00 0.95 1.00 0.5
Male 0.98(0.54~1.76) 0.84(0.45~1.57)
Stage of lung cancerb
I 1.00 1.00
II 2.08(1.35~3.20) <0.01a 1.89(1.12~2.93) <0.01a
III 6.26(4.33~9.05) <0.01a 5.27(3.58~7.74) <0.01a
IV 7.84(3.62~17.05) <0.01a 6.56(2.99~14.35) <0.01a
Smoking status
Non-smoker 1.00 0.44 1.00 0.92
Smoker or ex-smoker 0.86(0.59~1.25) 1.01(0.69~1.50)
Surgical approach
Lobectomy 1.00 <0.05a 1.00 0.50
Pneumonectomy 1.50(1.06~2.13) 0.88(0.61~1.27)
PS
0 1.00 <0.01a 1.00 <0.05a
1 8.21(3.33~20.00) 4.81(1.94~11.90)
aA p-value less than 0.05 was considered significant. HR = hazard ratio.
bAll patients were re-staged according to the 7th edition lung cancer staging. SCC = squamous cell carcinoma. TB = tuberculosis.
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patients with old TB lesions than in patients without TB
lesions. Those patients with old TB lesions who had EGFR
mutations or exon 19 mutations survived longer than
those who did not. Thus, we divided all 782 cases into 3
subgroups according to their histologic type. Although TB
may affect the immune system in all NSCLC cases, a cor-
relation between the presence of old TB lesions and sur-
vival outcomes was observed only in the SCC subgroup.
In the patients with EGFR-activating mutations, EGFR-
TKI treatment can be continued. This treatment is effective
against EGFR-activated cancers, providing an advantage in
cancer control of this group. In our study, TB did not
impact the survival of adenocarcinoma patients. Our study
is limited by the lack of information regarding the EGFR
mutation status in our patients; however, most cancer-
associated EGFR mutations occur in adenocarcinomas of
the lungs. Therefore, the shorter survival observed in the
SCC patients with old TB lesions is not likely to be due to
EGFR mutations.
Similar to other clinical studies with larger sample sizes,
in our study, SCC was the most common histological type
in the TB group [8,13,14]. Nalbandian [10] presented ex-
perimental evidence that chronic TB infection can trigger a
series of events that leads to extensive remodeling of lung
tissue or activation of a typical differentiation pathway
resulting in malignant transformation such as squamous
cell metaplasia. These authors also observed the genetic
control of SCC development induced by TB infection.
Conclusions
In conclusion, the presence of pulmonary TB is a negative
prognostic factor for SCC of the lung in Chinese patients.
More research is necessary to define common immuno-
logical pathways in TB and lung cancer.
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